Purpose Left ventricular hypertrophy (LVH) caused by systemic hypertension, myocardial infarction and congestive heart failure is associated with pathological changes in the structure of the heart, collectively described as remodelling (see part 1 of this review). The reversal of remodelling, termed cardioreparation, might restore cardiac structure and function towards normal, thereby improving the prognosis of these conditions. We aimed to explore the medical implications of this concept.
Data extraction Clinical trials of angiotensin converting enzyme (ACE) inhibitors and other drugs in patients with hypertension, myocardial infarction and congestive heart failure were reviewed. The results showed that ACE inhibitors induce regression of LVH in hypertensive patients, reduce mortality in acute myocardial infarction, and reduce morbidity and mortality in patients with congestive heart failure or left ventricular dysfunction subsequent to myocardial infarction. These observations are consistent with cardioreparation by ACE inhibitors.
Conclusions ACE inhibitors reduce morbidity and mortality in patients with myocardial infarction or congestive heart failure. Theoretical considerations and some clinical observations suggest that these benefits might result from cardioreparation.
KannelWB: Epidemiological implications of left ventricular hypertrophy In Left Ventricular Hypertrophy and its Regression. Edited by CruickshankJMMesserliFH.London: Science Press; 1992.
2.
WeberKTBrillaCGClelandJGF: Cardioreparation and the concept of modulating cardiovascular structure and functionBlood Pressure1993, 2:6–21.
3.
FischC: Electrocardiography and vectorcardiography. In Heart Disease: A Textbook of Cardiovascular Medicine. 4th Edition. Edited by BraunwaldE.Philadelphia: WB Saunders; 1992.
4.
McMahonSWWilckenELMacDonaldGJ: The effect of weight reduction on left ventricular mass: A randomized controlled trial in young, overweight hypertensive patientsN Engl J Med1986, 314:334–339.
5.
LevyDAndersonKMSavageDDKannelWBChristiansenJCCastelliWP: Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors: The Framingham Heart StudyArch Intern Med1988, 198:7–13.
6.
WeberKTBrillaCG: Pathological hypertrophy and cardiac interstitium: Fibrosis and the renin–angiotensin–aldosterone systemCirculation1991, 83:1849–1865.
7.
DahlöfBPennertKHanssonL: Reversal of left ventricular hypertrophy in hypertensive patients: A metaanalysis of 109 treatment studiesAm J Hypertens1992, 5:95–110.
8.
FagardRLijnenPStaessenJThijsLAmeryA: Mechanical and other factors relating to left ventricular hypertrophyBlood Pressure1994, 1 (suppl):5–10.
9.
CruickshankJM: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapyJ Hum Hypertens1992, 6:85–90.
10.
TrimarcoBDe LucaNRicciardelliB: Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophyAm J Cardiol1988, 62:745–750.
11.
GerstenblithGSchulmanSP: Influence of left ventricular mass regression on cardiac function in hypertensive elderly individualsEur J Clin Pharmacol1990, 39 (suppl 1):S25–S28.
12.
KorenMJWinRJLaraghJHDevereuxRB: Reduction in left ventricular mass during treatment of essential hypertension is associated with improved prognosis [abstract]Am J Hypertens1991, 4:1A–2A.
13.
MotzWSchwartzkopfBVogtM: Hypertensive heart disease: Cardio-reparation by reversal of interstitial collagen in patientsEur Heart J1995, 16 (suppl C):69–73.
14.
WhiteWBGeyHMSchulmanP: Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertensionAm Heart J1989, 118:782–795.
15.
HerpinDConteD: Assessment of the antihypertensive effect of lisinopril using 24-hour ambulatory monitoringJ Hum Hypertens1989, 3:11–15.
16.
KlonerRAEllisSGLangeRBraunwaldE: Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damageCirculation1983, 68:18–25.
17.
JugduttBIWarnicaJW: Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: Effect of timing, dose and infarct locationCirculation1988, 78:906–919.
18.
SharpeNMurphyJSmithHHannanS: Treatment of patients with symptomless left ventricular dysfunction following myocardial infarctionLancet1988, i:255–259.
19.
The International Collaborative Study Group: Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med1984; 310:9–15.
20.
The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI): A randomized placebo-controlled international trialEur Heart J1985, 6:199–226.
21.
ISIS-1 (First International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. ISIS-ILancet1986, ii:57–66.
22.
YusufSWittesJFriedmanL: Overview of results of randomized clinical trials in heart disease, I: Treatment following myocardial infarctionJAMA1988, 260:2088–2093.
23.
YusufSPetoRLewisJCollinsRSleightP: Beta blockade during and after myocardial infarction: An overview of the randomized trialsProg Cardiovasc Dis1985, 27:335–371.
ClelandJGF: The renin-angiotensin system in heart failureHerz1991, 16:68–81.
26.
GundersenT: Secondary prevention after myocardial infarction: Subgroup analysis of patients at risk in the Norwegian timolol multicentre studyClin Cardiol1985, 8:253–265.
27.
Beta-Blocker Pooling Project Research Group: The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post-infarction patientsEur Heart J1988, 9:8–16.
28.
GoldbourtUBeharSReichar-ReissHZionMMandelzweigLKaplinskyE: Early administration of nifedipine in suspected acute myocardial infarction: The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 StudyArch Intern Med1993, 153:345–353.
29.
FiferMAColucciWSLorellBHJaskiBEBarryWH: Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: Comparison with nitroprussideJ Am Coll Cardiol1985, 5:731–737.
30.
Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarctionN Engl J Med1988, 319:385–392.
31.
Danish Study Group on Verapamil in Myocardial Infarction: Verapamil in acute myocardial infarctionEur Heart J1984, 5:516–528.
32.
PfefferMABraunwaldEMoyéLABastaLBrownEJJrCuddyTE: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement TrialN Eng J Med1992, 327:669–677.
33.
Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failureLancet1993, 342:821–828.
34.
The TRACE study group: The TRAndalopril Cardiac Evaluation (TRACE) study: Rationale, design, and baseline characteristics of the screened populationAm J Cardiol1994, 73:44C–50C.
35.
Gruppo Italiano per lo Studio della Soppravvivenza nell'Infarto Miocardico: GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate, singly and together, on 6-week mortality and ventricular function after acute myocardial infarctionLancet1994, 343:1115–1120.
36.
SchipperheynJJ: GISSI 3: The results after six monthsCardiologie1994, 1:384–386.
37.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarctionLancet1995, 345:669–685.
38.
Chinese Cardiac Study Collaborative Group: Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1)Lancet1995, 345:686–687.
39.
AmbrosioniEBorghiCMagnaniB: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarctionN Engl J Med1995, 332:80–85.
40.
SwedbergKHeldPKjekshusJRasmussenKRydenLWedelH: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study (CONSENSUS-II)N Engl J Med1992, 327:678–684.
41.
KingmaJHvan GilstWHPeelsCH, For the CATS investigators: Acute intervention with captopril and thrombolysis study (CATS)Eur Heart J1994, 15:898–907.
42.
HochmanJSEdelsteinRPalmeriS: Captopril before reperfusion in acute myocardial infarction: The CAPTIN experience [abstract]J Am Cardiol1993, 21:37A.
43.
SchoemakerRGDebetsJJMStruyker-BoudierHAJSmitsJFM: Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarctionJ Mol Cell Cardiol1991, 23:187–197.
44.
PackerM: The neurohumoral hypothesis: A theory to explain the mechanism of disease progression in heart failureJ Am Coll Cardiol1992, 20:248–254.
45.
McFate SmithW: Epidemiology of congestive heart failureAm J Cardiol1985, 55:3A–8A.
46.
GoldbergADGoldsteinSNicklasJ, For the Imazodan Study group: Multicenter trial of imazodan in patients with chronic congestive heart failure [abstract]. Circulation1990, 80 (suppl III):III–673.
47.
PackerMMedinaNYushakM: Haemodynamic and clinical limitation of long-term inotropic therapy with amrinone in patients with severe chronic heart failureCirculation1984, 70:1038–1047.
48.
PackerMCarverJRRodehefferRJIvanhoeRJDiBiancoRZeidissM: Effect of oral milrinone on mortality in severe chronic heart failureN Engl J Med1991, 325:1468–1475.
49.
FergusonDWBergWJSandersJSRoachPJKempfJSKienzleMG: Sympatho-inhibitory responses to digitalis glycosides in heart failure patients: Direct evidence from sympathetic neural recordingsCirculation1989, 80:65–77.
50.
CovitABSchaerGLSealeyJELaraghJHCodyRJ: Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failureAm J Med1983, 75:445–447.
51.
GuyattGHSullivanMJJFallenELTibalHRideoutEHalcrowS: A controlled trial of digoxin in congestive heart failureAm J Cardiol1988, 61:371–375.
52.
de BonoD: Digoxin in eurhythmic heart failure: PROVED or not proven?Lancet1994, 343:128–129.
53.
CohnJNArchibaldDGZiescheSFranciosaJAHarstanWETristaniFE: Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative StudyN Engl J Med1986, 314:1547–1552.
54.
ClelandJGFOakleyCM: Vascular tone in heart failure: The neuroendocrine-therapeutic interfaceBr Heart J1991, 66:264–267.
55.
WaagsteinFBristowMRSwedbergKCameriniFFowlerMBSilverMA: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathyLancet1993, 342:1441–1446.
56.
CIBIS Investigators and Committees: A randomized trial of β-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS)Circulation1994, 90:1765–1773.
57.
PackerMBristowMRCohnJNFor the US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failureN Engl J Wed1996, 334:1349–1355.
58.
ElkayamUAminJMehraAVasquezJWeberLRahimtoolaSH: A prospective, randomized, double-blind crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failureCirculation1990, 82:1954–1961.
59.
GoldsteinREBoccuziSJCruessDNattelS, The Adverse Experience Committee, and the Multicentre Diltiazem Post-infarction Research Group: Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fractionCirculation1991, 83:52–60.
60.
ColucciWSFiferMALorellBHWynneJ: Calcium channel blockers in congestive heart failure: Theoretic considerations and clinical experienceAm J Wed1985, 78 (suppl 2B):9–17.
61.
SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failureN Engl J Med1991, 325:293–302.
62.
The CONSENSUS trial study group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)N Engl J Med1987, 316:1429–1435.
63.
CohnJNJohnsonGZiescheSCobbeFFrancisGTristaniFE: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failureN Engl J Med1991, 325:303–310.
64.
TanL-BJalilJEPickRJanickiJSWeberKT: Cardiac myocyte necrosis induced by angiotensin IICirc Res1991, 69:1185–1195.
65.
ClelandJGFDargieHJHodsmanGP: Captopril in heart failure. A double-blind controlled trialBr Heart J1984, 52:530–535.
